Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEMBROLA: Pembrolizumab + Olaparib in HRD mCRC
NCT05201612Phase 2Unknown
- Sponsor
- GEMCAD
- Start
- Jul 2022
- Primary completion
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, olaparib in metastatic colorectal cancer (mCRC), sponsored by GEMCAD. Status: unknown.
02
Drugs
pembrolizumabolaparib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05201612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05201612.